[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-nerve-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-nerve-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100643694","study-of-peripheral-neuropathy-in-patients-with-advanced-urothelial-cancer-treated-with-enfortumab-vedotin-and-pembrolizumab-with-supportive-neuridase-endeavor-100643694",false,"NCT07629700","Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR)","ENDEAVOR Study: A Prospective Exploratory Study Describing the Course of Peripheral Neuropathy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin in Combination With Pembrolizumab and Supportive Neuridase","ENDEAVOR","IInclusion Criteria:\n\n* Age ≥18 years\n* Histologically confirmed locally advanced or metastatic urothelial carcinoma\n* Candidate for treatment with enfortumab vedotin in combination with pembrolizumab according to clinical practice\n* Ability to provide written informed consent\n* Adequate clinical conditions to participate in the study according to investigator judgment\n\nExclusion Criteria:\n\n* Pre-existing severe peripheral neuropathy that may interfere with study assessments\n* Contraindications to enfortumab vedotin or pembrolizumab according to clinical practice\n* Known hypersensitivity to components of Neuridase\n* Pregnancy or breastfeeding\n* Any medical, psychiatric, or social condition that, in the investigator's judgment, may interfere with study participation or interpretation of results","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","his prospective exploratory study aims to describe the course of peripheral neuropathy in patients with locally advanced or metastatic urothelial carcinoma treated with enfortumab vedotin in combination with pembrolizumab and receiving supportive Neuridase.\n\nPeripheral neuropathy is a common adverse event associated with enfortumab vedotin and may negatively affect treatment tolerability, quality of life, and treatment continuation. Neuridase is a non-pharmacological supportive product intended to support peripheral nervous system function; however, its role in this clinical setting has not yet been established.\n\nParticipants enrolled in this single-arm study will receive standard-of-care treatment with enfortumab vedotin plus pembrolizumab, together with supportive Neuridase according to clinical practice. The study will prospectively assess neuropathy symptoms and severity using clinical evaluations and patient-reported outcome measures, including quality-of-life questionnaires, over the course of treatment.\n\nThe objective of the study is to explore neuropathy patterns and treatment tolerability in this patient population.",[27,28],"Urothelial Carcinoma (UC)","Peripheral Nerve Disease","NOT_YET_RECRUITING","2026-06-04",{"date":32,"type":33},"2026-06-08","ACTUAL",{"date":35,"type":21},"2026-09-01",{"date":37,"type":21},"2028-09-01",{"name":39,"class":40},"University of Florence","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100631708","phase-2-neuroprotection-of-memantine-and-rosuvastatin-100631708","NCT07504198","Neuroprotection of Memantine and Rosuvastatin","Neuroprotective Effect of Memantine and Rosuvastatin Against Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer","Inclusion criteria\n\n* Age above 18 years old for both gender .\n* Adequate baseline hematologic values (absolute neutrophil count ≥ 1.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL and hemoglobin level ≥ 10 g\u002Fdl).\n* Patients with adequate renal function (serum creatinine \\\u003C 1.5 mg\u002Fdl or creatinine clearance ˃ 45 mL\u002Fmin).\n* Patients with adequate liver function (serum bilirubin \\\u003C 1.5 mg\u002Fdl).\n* Patients with performance status \\\u003C2 according to Eastern Cooperative Oncology Group (ECOG) score.\n* Patients who will be scheduled to receive modified FOLFOX-6 or XELOX regimen.\n* Patients with histologically confirmed diagnosis of stage III or stage IV colorectal cancer.\n\nExclusion criteria:\n\n* Children \\\u003C 18 years old.\n* Prior exposure to neurotoxic chemotherapy (oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel, INH).\n* Patients with diabetes and other conditions that predispose to neuropathy as hypothyroidism, autoimmune diseases, hepatitis C.\n* History of known allergy to oxaliplatin or other platinum agents.\n* Patients with other inflammatory or stressful conditions.\n* Concomitant use of multivitamins (vitamins E, C, A), tricyclic antidepressants, other neuro-protective medications (gabapentin, lamotrigine, carbamazepine and phenytoin).\n* Patients on amantadine , acetazolamide, dextromethorphan, aluminum hydroxide magnesium hydroxide and febuxostat .\n* Concurrent active cancer originating from a primary site other than colon or rectum.\n* Pregnant and breastfeeding women.\n* Sever renal insufficiency (creatinine clearance \\\u003C 25 ml\u002F minute) .",{"count":49,"type":21},46,[51,52],"PHASE2","PHASE3","Memantine is used to slow the neurotoxicity of Alzheimer disease. Rosuvastatin used as a lipid-lowering agent . Increased bioavailability of endothelial-derived nitric oxide improves endothelium function , increases cerebral blood flow which may all contribute to the neuroprotective effects of rosuvastatin .\n\nThe goal of this clinical trial is to prevent oxaliplatin induced peripheral neuropathy in patients with colorectal cancer.The aim of this current study is to assess the neuroprotective effect of memantine and rosuvastatin against oxaliplatin induced peripheral neuropathy.",[28],"2026-03-25",{"date":57,"type":33},"2026-03-31",{"date":59,"type":21},"2026-03",{"date":61,"type":21},"2027-05",{"name":63,"class":40},"Tanta University",1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":17,"minAge":18,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":4,"briefSummary":76,"conditions":77,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":64},"100625239","turkish-adaptation-of-the-cts-6-evaluation-tool-a-validation-and-reliability-study-100625239","NCT07420049","Turkish Adaptation of the CTS-6 Evaluation Tool: A Validation and Reliability Study","1\\) INCLUSION CRITERIA:\n\nParticipants aged 18-60 years will be categorized into three groups:\n\n1. Healthy Control Group\n2. Group Presenting with CTS-like Symptoms\n3. Group Diagnosed with CTS Based on Defined Criteria\n\na) Healthy Control Group: Participants in this group will have no clinical symptoms consistent with CTS based on specified clinical criteria and will be considered normal according to the defined electrophysiological criteria.\n\nb) Group Presenting with CTS-like Symptoms: Participants in this group may exhibit symptoms similar to clinically defined CTS; however, electrophysiological evaluations will show normal findings according to the defined criteria.\n\nb.1) Clinical Findings \u002F Symptoms:\n\nb.1.1) Symptoms:\n\n(A) Sensory symptoms in any of the 1st, 2nd, 3rd, or the radial part of the 4th finger\n\n(B) Symptoms alleviated by shaking, squeezing, or other hand movements\n\n(C) Pain or paresthesia associated with gripping or hand use\n\n(D) Nocturnal paresthesia causing awakening from sleep\n\nb.1.2) Diagnostic Tests \u002F Signs:\n\n1. Tinel Sign\n2. Phalen Test\n3. Reverse Phalen Test\n4. Carpal Tunnel Compression Test\n5. Flick Sign\n\n   A clinical diagnosis of CTS will require symptoms persisting for at least three months, with at least one of the B, C, or D symptoms in addition to symptom A, plus at least one positive diagnostic test or sign.\n\n   b.2) Electrophysiological Evaluation:\n\n   b.2.1) Mild CTS:\n\n   Median-to-ulnar sensory distal latency difference ≥ 0.4 ms at the 4th finger\n\n   Median nerve sensory distal latency ≥ 2.8 ms at the 2nd finger\n\n   Median nerve conduction velocity \\\u003C 50 m\u002Fs\n\n   Sensory nerve action potential ≥ 12 µV\n\n   b.2.2) Moderate CTS:\n\n   Median nerve distal motor latency at Abductor Pollicis Brevis (APB) 4 ms ≤ x \\\u003C 6.5 ms\n\n   Median nerve conduction velocity \\\u003C 50 m\u002Fs\n\n   Compound Muscle Action Potential (CMAP) ≥ 5 mV\n\n   b.2.3) Severe CTS:\n\n   Median nerve distal motor latency at APB ≥ 6.5 ms\n\n   Median nerve conduction velocity \\\u003C 50 m\u002Fs and\u002For CMAP \\\u003C 5 mV\n\n   c) Group Diagnosed with CTS Based on Defined Criteria: Participants in this group meet the clinical diagnostic criteria for CTS and additionally fulfill electrophysiological evaluation criteria for mild, moderate, or severe CTS.\n\n2\\) EXCLUSION CRITERIA:\n\n2.a) Participants Diagnosed with CTS Based on Defined Criteria:\n\nHistory of cardiac pacemaker\n\nHistory of lymphedema in the affected extremity\n\nHistory of cervical radiculopathy\n\nPresence of ipsilateral upper extremity tenosynovitis\n\nPresence of another compressive neuropathy in the ipsilateral upper extremity\n\nHistory of peripheral polyneuropathy\n\nPresence of metabolic disease\n\nHistory of fracture in the hand, wrist, or forearm\n\nCurrent pregnancy\n\nOpen wound on the wrist\n\nUncontrolled medical conditions (including endocrinological, cardiovascular, pulmonary, hematological, hepatic, renal, active systemic inflammatory disease, and\u002For malignancy)\n\nHistory of inflammatory rheumatologic or autoimmune disease\n\nAge \\\u003C18 years or \\>60 years\n\nTrauma to the wrist or median nerve within the last 3 months\n\nReceived any injection in the wrist\n\nUndergone any surgical procedure on the wrist\n\nMental or cognitive incapacity preventing understanding or completion of questionnaires\n\n2.b) Participants Presenting with CTS-like Symptoms:\n\nMental or cognitive incapacity preventing understanding or completion of questionnaires\n\nAge \\\u003C18 years or \\>60 years\n\nCTS diagnosis confirmed based on clinical and electrophysiological criteria\n\n2.c) Healthy Control Group Participants:\n\nMental or cognitive incapacity preventing understanding or completion of questionnaires\n\nAge \\\u003C18 years or \\>60 years\n\nPresence of any clinical symptoms potentially related to CTS based on defined clinical criteria\n\nElectrophysiological findings consistent with CTS",true,"60 Years",{"count":74,"type":21},126,"OBSERVATIONAL","The purpose of this study is to develop the Turkish version of the CTS-6 Evaluation Tool and to comprehensively assess its validity and reliability in the Turkish population. The CTS-6 Evaluation Tool is a widely used and reliable instrument for the assessment of diagnosis and symptom severity in patients with carpal tunnel syndrome.\n\nIn this study, the CTS-6 will undergo translation and cultural adaptation to ensure linguistic and cultural appropriateness for the Turkish population. The goal is to produce a valid, reliable, and practical tool that can be used efficiently in clinical settings. The adapted version is intended to be applicable across multiple medical specialties involved in the diagnosis and management of carpal tunnel syndrome in Turkey. The results are expected to provide a trustworthy Turkish version of the CTS-6 suitable for both clinical practice and research purposes.",[78,79,28,80,81,82,83,84],"Carpal Tunnel Syndrome (CTS)","Median Nerve Entrapment","Peripheral Nerve Disorder","Reliability and Validity","Cross-cultural Adaptation","TURKISH VALIDITY AND RELIABILITY STUDY OF CTS-6 EVALUATİON TOOL","Diagnostic Tool",[86,87,88,89,90,91,84,92,93,94,95],"CTS-6 Evaluation Tool","CTS-6","Cross-cultural adaptation","Carpal Tunnel Syndrome","median nerve entrapment","reliability and validity","Peripheral nerve disease","Peripheral nerve disorders","Turkish version","Turkish Validity and Reliability Study of CTS-6 Evaluation Tool","2026-02-12",{"date":98,"type":33},"2026-02-19",{"date":100,"type":21},"2026-03-01",{"date":102,"type":21},"2026-07-01",{"name":104,"class":40},"Istanbul University"]